Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
New research has potential to alleviate side effects of cancer treatments

New research has potential to alleviate side effects of cancer treatments

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

NeuroMetrix second quarter total revenues decrease to $2.6 million

NeuroMetrix second quarter total revenues decrease to $2.6 million

Essential criteria for clinical diagnosis of restless legs syndrome

Essential criteria for clinical diagnosis of restless legs syndrome

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

NeuroMetrix to introduce NC-stat DPNCheck device for diabetic peripheral neuropathy

NeuroMetrix to introduce NC-stat DPNCheck device for diabetic peripheral neuropathy

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Foundation for Peripheral Neuropathy to launch first ever national PN research registry

Foundation for Peripheral Neuropathy to launch first ever national PN research registry

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium reports results from two VELCADE based combination studies against multiple myeloma

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis

YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis

Simple eye scan can detect early signs of diabetes-related nerve damage

Simple eye scan can detect early signs of diabetes-related nerve damage

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

China's SFDA approves TPI anti-diabetic drug Gliclazide

China's SFDA approves TPI anti-diabetic drug Gliclazide

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.